Edge Therapeutics Stock Company Profile

Description

Edge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes hospital-based therapies for acute life-threatening neurological conditions. Its lead product includes EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage. The company also develops EG-1964 for the management of chronic subdural hematoma as a prophylactic treatment to prevent recurrent bleeding. The company was founded in 2009 and is headquartered in Berkeley Heights, New Jersey.